About the Company
We do not have any company description for TScan Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.28 per share a year ago. These figures are ...
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue ... - Nasdaq
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.
TScan Therapeutics’s SWOT analysis: biotech stock faces pivotal year
TScan Therapeutics operates in the U.S. Small & Mid Cap Biotechnology sector, concentrating on innovative therapies for both hematological malignancies and solid tumors. The company’s primary focus ...
TScan Therapeutics Reports Q2 2025 Financial Results
Tscan Therapeutics, Inc. ( ($TCRX) ) has released its Q2 earnings. Here is a breakdown of the information Tscan Therapeutics, Inc. presented to ...
TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock ... - Nasdaq
Shares of TScan Therapeutics, Inc. Have increased 108.13% over the past quarter, and have gained 117.87% in the last year. On the other hand, the S&P 500 has only moved 4.59% and 14.85%, respectively.
TScan Therapeutics Reports Q3 2024 Financial Results
TScan Therapeutics, Inc. is a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies, primarily for cancer treatment, with a focus on hematologic ...
TCRX | TScan Therapeutics Inc. Profile | MarketWatch
TScan Therapeutics Inc. 830 Winter Street Waltham, Massachusetts 02451 Phone1 857 399-9500 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue$2.82M Net Income-$127.5M ...
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL ...
Heather Savelle (investors) TScan Therapeutics, Inc. VP, Investor Relations 857-399-9840 hsavelle@tscan.com Joyce Allaire LifeSci Advisors, LLC Managing Director 617-435-6602 jallaire ...
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral ...
Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center) A copy of the presentation materials will be added to the “Events and Presentations” section of the ...
Stifel Financial Corp Boosts Holdings in TScan Therapeutics, Inc ...
TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. On average, research analysts forecast that TScan Therapeutics, Inc. will post -1.12 EPS for ...
Similar Companies
Loading the latest forecasts...